LT4010082T - Daugiaspecifiniai anti-tcr delta kintami 1 antikūnai - Google Patents

Daugiaspecifiniai anti-tcr delta kintami 1 antikūnai

Info

Publication number: LT4010082T
Authority: LT; Lithuania
Prior art keywords: antibodies; tcr delta; multispecific anti; delta variable; variable
Prior art date: 2020-08-14

Application number

LTEPPCT/IB2021/057509T

Other languages

English (en)

Inventor

Mark Uden

Mihriban Tuna

Natalie MOUNT

Robert Good

Joshua Freedman

Shefali BHUMBRA

Oliver Nussbaumer

Raj Jaysukhlal MEHTA

Original Assignee

GammaDelta Therapeutics Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2020-08-14

Filing date

2021-08-14

Publication date

2023-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80247426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4010082(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2020-08-14 Priority claimed from PCT/GB2020/051959 external-priority patent/WO2021032963A1/en

2021-02-17 Priority claimed from GBGB2102222.3A external-priority patent/GB202102222D0/en

2021-02-17 Priority claimed from GBGB2102224.9A external-priority patent/GB202102224D0/en

2021-08-14 Application filed by GammaDelta Therapeutics Limited filed Critical GammaDelta Therapeutics Limited

2023-03-10 Publication of LT4010082T publication Critical patent/LT4010082T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Oncology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Steroid Compounds (AREA)

LTEPPCT/IB2021/057509T 2020-08-14 2021-08-14 Daugiaspecifiniai anti-tcr delta kintami 1 antikūnai LT4010082T (lt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
PCT/GB2020/051959 WO2021032963A1 (en)	2019-08-16	2020-08-14	Therapeutic uses of anti-tcr delta variable 1 antibodies
GBGB2102222.3A GB202102222D0 (en)	2021-02-17	2021-02-17	Multispecific anti-TCR delta variable 1 antibodies
GBGB2102224.9A GB202102224D0 (en)	2021-02-17	2021-02-17	Anti-TRC delta variable 1 antibodies
PCT/IB2021/057509 WO2022034562A1 (en)	2020-08-14	2021-08-14	Multispecific anti-tcr delta variable 1 antibodies

Publications (1)

Publication Number	Publication Date
LT4010082T true LT4010082T (lt)	2023-03-10

Family

ID=80247426

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP23187269.8T LT4269444T (lt)	2020-08-14	2021-08-14	Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
LTEPPCT/IB2021/057509T LT4010082T (lt)	2020-08-14	2021-08-14	Daugiaspecifiniai anti-tcr delta kintami 1 antikūnai

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LTEP23187269.8T LT4269444T (lt)	2020-08-14	2021-08-14	Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai

Country Status (18)

Country	Link
EP (7)	EP4218932A3 (lt)
JP (1)	JP7847579B2 (lt)
KR (1)	KR20230083267A (lt)
CN (1)	CN116209456A (lt)
AU (1)	AU2021323512A1 (lt)
BR (1)	BR112023002741A2 (lt)
CA (1)	CA3188682A1 (lt)
CO (1)	CO2023003009A2 (lt)
DK (2)	DK4010082T4 (lt)
ES (2)	ES2993071T3 (lt)
FI (2)	FI4269444T3 (lt)
IL (1)	IL300517A (lt)
LT (2)	LT4269444T (lt)
MX (1)	MX2023001728A (lt)
PL (2)	PL4010082T5 (lt)
PT (2)	PT4010082T (lt)
SI (2)	SI4010082T1 (lt)
WO (1)	WO2022034562A1 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT4269444T (lt)	2020-08-14	2024-09-25	GammaDelta Therapeutics Limited	Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
JP2025519645A (ja) *	2022-06-23	2025-06-26	ラヴァ・セラピューティクス・エヌ・ヴイ	Ｔ細胞依存性多重特異性化合物のアッセイ
EP4680729A1 (en) *	2023-03-17	2026-01-21	Legend Biotech Ireland Limited	Methods of culturing v delta 1 t cells
WO2025147597A1 (en) *	2024-01-05	2025-07-10	Eugit Therapeutics, Inc.	Targeting payloads
WO2025191133A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en)	2024-03-15	2025-09-18	Avidicure Ip B.V.	Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2546268A1 (en)	2011-07-13	2013-01-16	F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H.	Internalising immunoglobulin
WO2015063069A1 (en) *	2013-10-28	2015-05-07	Benjamin Felder	Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors
GB201506423D0 (en) *	2015-04-15	2015-05-27	Tc Biopharm Ltd	Gamma delta T cells and uses thereof
AU2016274633B2 (en)	2015-06-09	2022-04-21	Gammadelta Therapeutics Ltd	Methods for the production of TCR gamma delta+ T cells
CN108137691B (zh) *	2015-09-02	2021-10-19	耶路撒冷希伯来大学伊萨姆研究发展有限公司	特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
EP4148124A1 (en)	2015-10-30	2023-03-15	Cancer Research Technology Limited	Expansion of non-haematopoietic tissue-resident gamma delta t cells and uses of these cells
EP3454870A4 (en)	2016-05-12	2020-03-04	Adicet Bio Inc.	METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
GB201612520D0 (en)	2016-07-19	2016-08-31	F-Star Beta Ltd	Binding molecules
CA3032304A1 (en)	2016-07-29	2018-02-01	New York University	Gamma delta t cells as a target for treatment of solid tumors
US10546518B2 (en)	2017-05-15	2020-01-28	Google Llc	Near-eye display with extended effective eyebox via eye tracking
EP3645050A4 (en)	2017-06-25	2021-08-11	Systimmune, Inc.	Multi-specific antibodies and methods of making and using thereof
US10519236B2 (en)	2018-01-23	2019-12-31	New York University	Antibodies specific to delta 1 chain of T cell receptor
WO2020060406A1 (en)	2018-09-19	2020-03-26	Lava Therapeutics B.V.	Novel bispecific antibodies for use in the treatment of hematological malignancies
GB201818243D0 (en)	2018-11-08	2018-12-26	Gammadelta Therapeutics Ltd	Methods for isolating and expanding cells
US12084500B2 (en) *	2019-01-23	2024-09-10	New York University	Antibodies specific to delta 1 chain of T cell receptor
CN113993893A (zh) *	2019-02-01	2022-01-28	拉法医疗有限公司	新cd40结合抗体
JP7730295B2 (ja)	2019-04-08	2025-08-27	メモリアルスローンケタリングキャンサーセンター	Ｃｄ１９抗体およびこれを使用する方法
US20220290101A1 (en)	2019-08-16	2022-09-15	GammaDelta Therapeutics Limited	Ex vivo gamma delta t cell populations
CA3145523A1 (en) *	2019-08-16	2021-02-25	GammaDelta Therapeutics Limited	Therapeutic uses of anti-tcr delta variable 1 antibodies
LT4269444T (lt)	2020-08-14	2024-09-25	GammaDelta Therapeutics Limited	Daugiaspecifiniai anti-tcr kintamos delta 1 antikūnai
TW202246338A (zh)	2021-02-17	2022-12-01	英商適應生物治療有限公司	抗ＴＣＲδ可變1抗體

2021
- 2021-08-14 LT LTEP23187269.8T patent/LT4269444T/lt unknown
- 2021-08-14 PL PL21756070.5T patent/PL4010082T5/pl unknown
- 2021-08-14 BR BR112023002741A patent/BR112023002741A2/pt unknown
- 2021-08-14 MX MX2023001728A patent/MX2023001728A/es unknown
- 2021-08-14 EP EP23153152.6A patent/EP4218932A3/en active Pending
- 2021-08-14 CN CN202180069269.3A patent/CN116209456A/zh active Pending
- 2021-08-14 WO PCT/IB2021/057509 patent/WO2022034562A1/en not_active Ceased
- 2021-08-14 EP EP23187272.2A patent/EP4269445B1/en active Active
- 2021-08-14 EP EP23187273.0A patent/EP4269446B1/en active Active
- 2021-08-14 CA CA3188682A patent/CA3188682A1/en active Pending
- 2021-08-14 JP JP2023510439A patent/JP7847579B2/ja active Active
- 2021-08-14 DK DK21756070.5T patent/DK4010082T4/da active
- 2021-08-14 SI SI202130032T patent/SI4010082T1/sl unknown
- 2021-08-14 PT PT217560705T patent/PT4010082T/pt unknown
- 2021-08-14 LT LTEPPCT/IB2021/057509T patent/LT4010082T/lt unknown
- 2021-08-14 EP EP23187270.6A patent/EP4265642B1/en active Active
- 2021-08-14 DK DK23187269.8T patent/DK4269444T5/da active
- 2021-08-14 AU AU2021323512A patent/AU2021323512A1/en active Pending
- 2021-08-14 SI SI202130192T patent/SI4269444T1/sl unknown
- 2021-08-14 ES ES23187269T patent/ES2993071T3/es active Active
- 2021-08-14 IL IL300517A patent/IL300517A/en unknown
- 2021-08-14 EP EP23187271.4A patent/EP4265643B1/en active Active
- 2021-08-14 KR KR1020237005145A patent/KR20230083267A/ko active Pending
- 2021-08-14 FI FIEP23187269.8T patent/FI4269444T3/fi active
- 2021-08-14 EP EP21756070.5A patent/EP4010082B9/en active Active
- 2021-08-14 FI FIEP21756070.5T patent/FI4010082T4/fi active
- 2021-08-14 PT PT231872698T patent/PT4269444T/pt unknown
- 2021-08-14 EP EP23187269.8A patent/EP4269444B1/en active Active
- 2021-08-14 PL PL23187269.8T patent/PL4269444T3/pl unknown
- 2021-08-14 ES ES21756070T patent/ES2943063T3/es active Active
2023
- 2023-03-13 CO CONC2023/0003009A patent/CO2023003009A2/es unknown

Also Published As

Publication number	Publication date
DK4010082T4 (en)	2026-02-16
PT4010082T (pt)	2023-04-26
EP4265642B1 (en)	2024-06-26
EP4218932A2 (en)	2023-08-02
FI4010082T3 (fi)	2023-04-04
AU2021323512A1 (en)	2023-04-13
LT4269444T (lt)	2024-09-25
EP4010082B1 (en)	2023-01-25
FI4269444T3 (fi)	2024-09-20
PL4010082T3 (pl)	2023-05-29
EP4265642A2 (en)	2023-10-25
EP4265643A2 (en)	2023-10-25
DK4269444T3 (en)	2024-08-19
BR112023002741A2 (pt)	2023-10-10
DK4010082T3 (da)	2023-04-03
KR20230083267A (ko)	2023-06-09
IL300517A (en)	2023-04-01
WO2022034562A1 (en)	2022-02-17
EP4218932A3 (en)	2023-09-27
ES2943063T3 (es)	2023-06-08
EP4010082B2 (en)	2025-12-31
FI4010082T4 (fi)	2026-03-24
EP4269446A3 (en)	2024-02-14
DK4010082T5 (da)	2024-08-05
EP4265643A3 (en)	2024-02-14
MX2023001728A (es)	2023-04-20
EP4269445B1 (en)	2024-06-26
PT4269444T (pt)	2024-09-05
CO2023003009A2 (es)	2023-03-17
EP4269444A3 (en)	2024-02-14
EP4269446A2 (en)	2023-11-01
SI4269444T1 (sl)	2024-10-30
DK4269444T5 (da)	2024-08-26
EP4269444B1 (en)	2024-06-26
EP4269446B1 (en)	2024-06-26
JP7847579B2 (ja)	2026-04-17
ES2993071T3 (en)	2024-12-20
PL4269444T3 (pl)	2025-01-13
CN116209456A (zh)	2023-06-02
JP2023537534A (ja)	2023-09-01
EP4269445A3 (en)	2024-02-14
EP4010082B9 (en)	2026-03-04
EP4265642A3 (en)	2024-02-14
PL4010082T5 (pl)	2026-03-09
EP4265643B1 (en)	2024-06-26
CA3188682A1 (en)	2022-02-17
EP4269444A2 (en)	2023-11-01
EP4010082A1 (en)	2022-06-15
SI4010082T1 (sl)	2023-04-28
EP4269445A2 (en)	2023-11-01

Publication	Publication Date	Title
DK4269444T3 (en)	2024-08-19	Multispecific anti-tcr delta variable 1 antibodies
IL292727A (en)	2022-07-01	Multispecific antibodies
IL308741A (en)	2024-01-01	Anti-SIRP-alpha antibodies
ZA202308120B (en)	2024-12-18	Multispecific anti-tcr delta variable 1 antibodies
PT4214240T (pt)	2024-11-25	Anticorpos anti-ccr8
GB202105110D0 (en)	2021-05-26	Anti-CD73 antibodies
GB202111905D0 (en)	2021-10-06	Antibodies
GB202014851D0 (en)	2020-11-04	SARS-COV-2 antibodies
IL300142A (en)	2023-03-01	Anti-IL13Ralpha2 antibodies
GB202111685D0 (en)	2021-09-29	Anti-tcr delta variable 1 antibodies
GB202102222D0 (en)	2021-03-31	Multispecific anti-TCR delta variable 1 antibodies
GB202010652D0 (en)	2020-08-26	Anti-tau antibodies
HK40104958A (en)	2024-08-02	Multispecific anti-tcr delta variable 1 antibodies
GB202203226D0 (en)	2022-04-20	Trays
IL307332A (en)	2023-11-01	New multispecific antibodies
IL308782A (en)	2024-01-01	Antibodies
IL308100A (en)	2023-12-01	Antibodies
GB202102227D0 (en)	2021-03-31	Antibodies
GB202102224D0 (en)	2021-03-31	Anti-TRC delta variable 1 antibodies
HK40105359A (en)	2024-08-09	Anti-tcr delta variable 1 antibodies
HK40076337A (en)	2023-02-10	Novel anti-tcr delta variable 1 antibodies
GB202008022D0 (en)	2020-07-15	Antibodies
HK40072486A (en)	2022-11-25	Therapeutic uses of anti-tcr delta variable 1 antibodies
HK40110498A (en)	2024-12-20	Anti-polyubiquitin multispecific antibodies
GB202208773D0 (en)	2022-07-27	Anti-SARS2-S antibodies